You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for ATOVAQUONE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ATOVAQUONE

Average Pharmacy Cost for ATOVAQUONE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ATOVAQUONE 750 MG/5 ML SUSP 16714-0900-01 0.83438 ML 2025-01-22
ATOVAQUONE 750 MG/5 ML SUSP 62135-0528-09 0.83438 ML 2025-01-22
ATOVAQUONE 750 MG/5 ML SUSP 65162-0693-88 0.83438 ML 2025-01-22
ATOVAQUONE 750 MG/5 ML SUSP 31722-0629-21 0.83438 ML 2025-01-22
ATOVAQUONE-PROGUANIL 62.5-25 68462-0402-01 1.27027 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for ATOVAQUONE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
ATOVAQUONE 750MG/5ML SUSP,ORAL Golden State Medical Supply, Inc. 51407-0642-87 210ML 395.01 1.88100 ML 2023-06-15 - 2028-06-14 FSS
ATOVAQUONE 750MG/5ML SUSP,ORAL AvKare, LLC 65162-0693-88 210ML 847.04 4.03352 ML 2023-06-15 - 2028-06-14 FSS
ATOVAQUONE 750MG/5ML SUSP,ORAL Golden State Medical Supply, Inc. 66689-0062-18 18X5ML 628.35 2023-06-16 - 2028-06-14 FSS
ATOVAQUONE 750MG/5ML SUSP,ORAL Golden State Medical Supply, Inc. 66689-0062-42 42X5ML 948.00 2023-06-16 - 2028-06-14 FSS
MEPRON SUSPENSION 750MG/5ML GlaxoSmithKline 00173-0665-18 1X210 1464.72 2023-01-01 - 2027-07-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Atovaquone Market Analysis and Price Projections

Introduction to Atovaquone

Atovaquone is an antiprotozoal medication commonly used in combination with proguanil for the treatment and prevention of malaria, as well as for other conditions such as babesiosis and pneumocystis pneumonia. Here, we will delve into the market analysis and price projections for Atovaquone, both in its standalone form and in combination with proguanil.

Global Market Size and Growth

The global Atovaquone and Proguanil market is significant and growing. As of 2024, the market size was estimated at USD 185.6 million, with a projected growth to USD 397.65 million by 2031, reflecting a compound annual growth rate (CAGR) of 11.5% from 2024 to 2031[1].

Regional Market Breakdown

  • North America: This region dominated the market in 2024, with a market size of USD 74.24 million. The growth is driven by increased travel to malaria-endemic areas and a strong healthcare infrastructure. The CAGR for North America is expected to be around 9.7% from 2024 to 2031[1].
  • Europe: Europe is the fastest-growing region, driven by global travel and a focus on malaria prevention. The strong healthcare structures and emphasis on travel medicine contribute to the demand for Atovaquone/Proguanil[1].
  • Asia Pacific: This region held around 23% of the global revenue in 2024, with a market size of USD 42.69 million. The CAGR for Asia Pacific is expected to be 13.5% from 2024 to 2031[1].
  • Latin America and Middle East & Africa: These regions also show significant growth, with Latin America expected to grow at a CAGR of 10.9% and the Middle East & Africa at a CAGR of 11.2% from 2024 to 2031[1].

Market Drivers

Several factors drive the growth of the Atovaquone market:

  • Increasing Incidence of Malaria and Protozoal Infections: The rising burden of malaria and other protozoal infections globally is a major driver. As travel to endemic areas increases, so does the demand for effective antimalarial medications[4].
  • Advancements in Drug Delivery Technologies: Improvements in drug delivery systems and formulations enhance the efficacy and patient compliance, contributing to market growth[4].

Pricing and Cost Analysis

Atovaquone Pricing

  • Oral Suspension: The cost for atovaquone (750 mg/5 mL) oral suspension is around $194 for a supply of 90 milliliters. This price can vary depending on the pharmacy and is based on cash-paying customers[2].

Atovaquone/Proguanil Pricing

  • Oral Tablets: The cost for atovaquone/proguanil (250 mg-100 mg) oral tablets is approximately $40 for a supply of 14 tablets. For the pediatric formulation (62.5 mg-25 mg), the cost is around $95.43 for 100 tablets[5].

Competitive Landscape

The Atovaquone and Proguanil market is competitive, with several key players:

  • GSK: Known for the brand name Malarone, which is a combination of atovaquone and proguanil.
  • Glenmark: Offers generic versions of atovaquone and atovaquone/proguanil.
  • Mylan Pharmaceuticals: Another major player in the generic market.
  • Hetero: Also provides generic formulations of these medications[3].

Market Segmentation

The market is segmented based on type and application:

  • Type: Atovaquone is available in various formulations, including 250 mg and 500 mg tablets, and oral suspensions.
  • Application: The primary applications are in hospitals and drug stores, with a focus on both adult and pediatric patients[4].

Future Projections

By 2032, the global Atovaquone market is expected to reach USD 0.338 billion, exhibiting a CAGR of 6.2% from 2023 to 2032. This growth is driven by the increasing incidence of malaria and advancements in drug delivery technologies[4].

Regional Growth Projections

  • Asia Pacific: Expected to grow at a CAGR of 13.5%, driven by increasing travel and a growing focus on healthcare infrastructure[1].
  • Europe: Will continue to be a fast-growing region due to heightened travel to malaria-endemic areas and strong healthcare systems[1].

Key Takeaways

  • The global Atovaquone and Proguanil market is projected to grow significantly, driven by the rising burden of malaria and advancements in drug delivery.
  • North America and Europe are key markets, with Asia Pacific showing the highest growth rate.
  • Pricing varies by formulation and region, with generic options available from multiple manufacturers.
  • The market is expected to reach USD 397.65 million by 2031, with a CAGR of 11.5% from 2024 to 2031.

FAQs

What is the current global market size for Atovaquone and Proguanil?

The global Atovaquone and Proguanil market size was estimated at USD 185.6 million in 2024[1].

What is the projected growth rate for the Atovaquone and Proguanil market from 2024 to 2031?

The market is expected to grow at a CAGR of 11.5% from 2024 to 2031[1].

Which region dominates the Atovaquone and Proguanil market?

North America dominates the market, holding more than 40% of the global revenue in 2024[1].

What are the main drivers of the Atovaquone market?

The main drivers include the increasing incidence of malaria and protozoal infections, and advancements in drug delivery technologies[4].

Who are the key players in the Atovaquone and Proguanil market?

Key players include GSK, Glenmark, Mylan Pharmaceuticals, and Hetero[3].

What is the expected market size for Atovaquone by 2032?

The global Atovaquone market is expected to reach USD 0.338 billion by 2032[4].

Sources

  1. Cognitive Market Research: Atovaquone and Proguanil Market Report 2024 (Global Edition)
  2. Drugs.com: Atovaquone Prices, Coupons, Copay Cards & Patient Assistance
  3. Valuates Reports: Atovaquone and Proguanil - Market Size
  4. Business Research Insights: Atovaquone Market Size, Share, Growth, 2032 | Global Research
  5. Drugs.com: Atovaquone/proguanil Prices, Coupons, Copay Cards & Patient Assistance

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.